Trial result ·
Getting to Implementation: applying data-driven implementation strategies to improve guideline concordant surveillance for hepatocellular carcinoma.
Written based on 1 research study on PubMed, searched on 3 Nov 2026.
What was studied
This was a stepped-wedge, cluster-randomized trial at 12 Veterans Health Administration (VA) sites. The sites were underperforming. It ran from October 2020 to October 2022. The aim was better liver cancer (HCC) surveillance in people with cirrhosis. Adherence to guidelines varies. The tested approach was Getting to Implementation (GTI). It is a manualized facilitation approach. GTI guided sites through steps. They set goals, found barriers and picked strategies. They made a work plan, did an evaluation and sustained the work.
What they found
Facilitators gave site teams an average of 20 ± 6 hours over 12 months. Most of the 12 sites adopted GTI. They applied several strategies, such as dashboard use and direct patient outreach. Reach was the primary outcome. It is the share of at-risk Veterans getting HCC surveillance. It rose from a mean of 29.1 to 38.8. It rose further to 41.3 in the sustainment period. The odds of surveillance were significantly higher during the intervention. The adjusted odds ratio (aOR) was 1.67 (CI 1.59 to 1.75). Odds were higher in sustainment (aOR 1.69, CI 1.60 to 1.78).
What it means for patients
The authors say GTI sustainably improved HCC surveillance. They say data-driven strategies delivered through manualized facilitation can improve care.
Why it is not certain yet
Some of the 12 sites did not adopt GTI. All sites were VA sites that were underperforming at the start. The abstract does not say whether patient health outcomes improved.
The registered trial
The paper names this trial from a public trial registry. Its page shows who the trial is for, its sites and its status.
Source
Getting to Implementation: applying data-driven implementation strategies to improve guideline concordant surveillance for hepatocellular carcinoma.
PubMed · PMID 41388318We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Liver and biliary tract cancer publications